FDA Warns Fresenius on Kidney Dialysis Devices

The FDA has sent a warning to Fresenius Medical Case Holdings Inc. that th company has not taken sufficients steps to address a faulty product, the Liberty Casetts a disposable part for dialysis machines. Over 118 complains said that the devices leaked causing adverse patient reactions and cases of peritonitis. No recall has been...
Continue reading…

Johnson & Johnson secret recall of Motrin investigated

Congress is investigating the Johnson & Johnson company for secretly buying back Motrin tablets from stores in a phantom recall of defective products without publicly notifying the buying public. The children's medicines were pulled after FDA inspectors found defective manufacturing process, bacterial contamiantion of raw materials. Rather than announcing the recall, the drug company...
Continue reading…

WARNING POSTED: FOSAMAX THIGH BONE FRACTURES

An expert panel convened by the American Society of Bone and Mineral Research has recommended new warnings on Fosamax for bone fractures. Fosamax is prescribed for treatment of osteoporosis and is used by more than 20 million people having generated over $3 billion in annual sales for Merck. A number of lawsuits have been...
Continue reading…

LAWSUITS MOUNT OVER DEPUY HIP IMPLANT RECALL OF 93,000

Several lawsuits have now been filed over the Johnson & Johnson DePuy ASR hip implant which has been recalled worldwide after data revealed a very high failure rate. Over 93,000 people around the world have received one of the defective hip implants. Patients report pain, swelling, Inflammation and infection surrounding the bone and tissue....
Continue reading…

ZOCOR, 13 OTHER DRUGS MAKE FDA LIST OF MEDS OF CONCERN

The FDA has released its quarterly list of medications being monitored for advese event reports for the second quarter of 2010. Included on the list is the popular cholesterol drug Zocor now linked to a series and potentially life-threatening muscle disease rhabdomyolysis. The agency also identified potential signals for serious risk associated with Cleocin,...
Continue reading…

Pharma Co Intermune paya $36.9 million to settle whislteblower suit

Intermune Inc. of California will pay the U.S $36.9 million to settle a False Claims Act case for misleading methods of drug marketing to patients for treatments never approved. The company marketed Actimmune for tretament of idiopathic pulmonary fibrosis which the FDA had not approved . The whistleblower will receive 25% of the settlement.